- Arvinas went public at $16 on September 26, 2018. The stock zoomed to $92.77 on the early trial successes of its two oncology targets. and currently trades at $67.18.
- Pfizer has a cooperation with Arvinas, which the latter shows may deliver another $802 million potential revenue. Little has been said about this cooperation since its announcement.
- Arvinas is a pioneer in using targeted protein degradation to cure various maladies. Pfizer and their Covid vaccine partner BioNTech know all about the proteins involved in SARS CoV-2.
- On May 19, 2021, the CEO of Arvinas competitor Progenra (private) gave a talk on using protein degradation for SARS-CoV-2. So protein degradation is definitely on the radar for SARS-CoV-2.
For further details see:
Connecting The Dots: Are Pfizer And Arvinas At Work On A COVID Cure?